Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Jul;11(4):219-23.
doi: 10.1007/BF00917428.

Light-chain ratio of serum IgA1 in IgA nephropathy

Affiliations

Light-chain ratio of serum IgA1 in IgA nephropathy

S H Chui et al. J Clin Immunol. 1991 Jul.

Abstract

Patients with primary IgA nephropathy have deposits of IgA1 in their kidneys and increased IgA1 in circulation. We had previously shown that IgA nephritic patients displayed a unique immunological response characterized by a predominance of IgA with lambda chain in glomerular deposits and in circulation. We have now studied the kappa/lambda (kappa/lambda) ratio of serum IgA1 in 21 IgA nephritic patients at quiescence, with 11 patients investigated during exacerbation as well. A novel enzyme-linked immunosorbent assay was used with monoclonal mouse anti-human IgA1 as the solid-phase capture antibody and peroxidase-labeled anti-human kappa and lambda antibodies as tracers. The ratio of serum IgA1 to total IgA (mean +/- SD) was significantly higher in patients (90.1 +/- 8.2% at quiescence, P less than 0.01; 88.7 +/- 8.1% during exacerbation, P less than 0.02) than in 20 healthy age- and sex-matched controls (80.0 +/- 9.8%). Furthermore, serum IgA1 kappa/lambda ratios were significantly lower in patients (1.02 +/- 0.27 at quiescence, P less than 0.01; 0.93 +/- 0.16 during exacerbation, P less than 0.01) than in controls (1.31 +/- 0.30). These findings indicate a predominance of lambda light-chain IgA1 in the serum of IgA nephritic patients. However, no difference in IgA1 kappa/lambda ratio was observed in these patients at quiescence and during exacerbation.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Immunol Immunopathol. 1983 Mar;26(3):390-7 - PubMed
    1. Clin Nephrol. 1988 Dec;30(6):330-4 - PubMed
    1. J Clin Immunol. 1989 Nov;9(6):485-92 - PubMed
    1. Clin Chem. 1990 Mar;36(3):501-2 - PubMed
    1. Am J Kidney Dis. 1988 Nov;12(5):348-52 - PubMed

Publication types

Substances

LinkOut - more resources